Welcome to TheraVasc

TheraVasc, Inc., located in Cleveland, Ohio is dedicated to reducing the risk, cost and time associated with drug developement by focusing on developing repurposed drugs for unserved vascular disease markets. The Company is focusing its efforts on targeting diseases for which no effective therapies currently exist and that result in a terrible quality of life or rapidly progress to death. TheraVasc's initial product, TV1001 (an oral formulation of sodium nitrite) targets patient populations with poor blood flow to the extremities, such as those with diabetic leg and foot problems or those with peripheral artery disease (PAD). While there are a large and growing number of patients suffering from each of these diseases, there are no effective treatments available. A recent opinion article from leading clinical experts on PAD and angiogeneses in the premier scientific journal 'Nature" concludes that a new finding revives "hope that a drug might one day be available." The off-patent drug referenced in this article is licensed by TheraVasc and has been shown to selectively promote the re-growth of blood vessesl only in ischemic tissues such as those affected in patients with diabetes or by PAD. The Company is currently in clinical development with this compound.

 

 

12/30/09: JumpStart and Portal capital invest in TheraVasc . . . complete press release

08/19/09: Theravasc Awarded “Most Promising Life Science Technology Company” at Rice Alliance Life Science Venture Forum . . . complete press release

Kumar D., et al. (2008) Chronic sodium nitrite therapy augments ischemia-induced angiogenesis and arteriogenesis . . . read publication

Kevil, C., Patel, R. (2008) Preserving vessel function during ischemic disease: new possibilities for inorganic
nitrite therapy . . . read publication